Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral Agents Treatment for Patients with Genotype 3/6 Hepatitis C Virus Infection

Table 2

The virological response of DAAs treatment.

	All (n = 54)	CHC (n = 39)	CIR (n = 15)	Statistics
Regimen (1/2/3/4/5)	16/17/12/7/2	12/16/4/7/0	4/1/8/0/2	18.823	<0.001
RVR	32/46 (69.6%)	24/32 (75.0%)	8/14 (57.1%)	0.745	0.388
EVR	45/46 (97.8%)	31/31(100%)	14/15 (93.3%)	—	0.326
EOTR	53 (98.1%)	39 (100%)	14 (93.3%)	—	0.278
SVR12	51 (94.4%)	38 (97.4%)	13 (86.7%)	—	0.183
Relapse	3 (5.6%)	1 (2.6%)	2 (13.3%)	—	0.183

CHC: chronic hepatitis C; CIR: cirrhosis; Regimen: 1 = SOF + RBV, 2 = SOF + DCV, 3 = SOF + DCV + RBV, 4 = SOF/VEL, and 5 = SOF/VEL + RBV, 12 weeks or 24 weeks; RVR: rapid virological response; EVR: early virological response; EOTR: end of treatment response; SVR12: sustained virological response 12 weeks after the end of treatment.